Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial thrombosis and carotid atherosclerosis in type 2 diabetes

Summary

To determine the genotype distributions of the polymorphisms in platelet glycoproteins (GP) Ib-alpha, Ia/IIa and IIb/IIIa and their association with clinical arterial thrombosis and preclinical carotid atherosclerosis in type 2 diabetes we studied 229 patients with type 2 diabetes and 229 controls matched by age, gender and ethnicity. Biochemical and haemostasis analyses were performed. The GP Ib-alpha VNTR, GP Ia 807 C/T and GP IIIa Pl(A) polymorphisms were determined by PCR. Thrombotic events were registered and carotid atherosclerosis was evaluated by ultrasound examination. A total of 107 patients had clinical atherothrombosis (CA), 65 subclinical atherosclerosis (SA), and 57 had no evidence of atherosclerosis (NA). There were no differences in allele frequencies and the genotype distribution of platelet GP polymorphisms between diabetic patients and controls. The VNTR Ib-alpha polymorphism was not associated with CA. We found a significant association between CA and the 807T (odds ratio [OR]: 2.86, confidence interval [CI]: 1.65–4.93; p<0.001) and PlA2 (OR: 2.03, CI: 1.13–3.65; p=0.03) alleles (in GP Ia and GP IIIa, respectively) in comparison to SA and NA group. Diabetic patients with the coexistence of the 807T and PlA2 alleles presented the highest risk of CA (OR: 3.59, CI: 1.64–7.8; p<0.001). The coexistence of both 807T and PlA2 alleles was also associated with the presence of SA (OR: 9.00, CI: 1.10–73.42; p=0.04). In conclusion, the 807T allele of GP Ia and the PlA2 allele of GP IIIa, and specially its combination, may confer an additional risk for development of carotid atherosclerosis and arterial thrombosis in type 2 diabetes.

Keywords

Arterial thrombosis - carotid atherosclerosis - platelet glycoprotein - polymorphism - type 2 diabetes

• References

• 1 Buse JB, Ginsberg HN, Bakris GL. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126.
• 2 Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. Am J Cardiol 2008; 51: 944-955.
• 3 Colwell JA, Nesto RW. The platelets in diabetes. Diabetes Care 2003; 26: 2181-2188.
• 4 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
• 5 Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost. 2008; 99: 480-486.
• 6 Tschoepe D, Roesen P, Schwippert B. et al. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993; 19: 122-128.
• 7 Nurden AT. Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost 1995; 74: 345-351.
• 8 Moroi M, Jung SM, Yoshida N. Genetic polymorphism of platelet glycoprotein Ib. Blood 1984; 64: 622-629.
• 9 Zhang Y, Wang Y, Wang Y. et al. Platelet glycoprotein polymorphisms: risk, in vivo expression and severity of atherothrombotic stroke in Chinese. Clin Chim Acta 2007; 378: 99-104.
• 10 Carter AM, Catto AJ, Bamford JM. et al. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol 1998; 18: 1124-1131.
• 11 Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002; 22: 14-20.
• 12 Moshfegh K. Association of two silent polymorphisms of platelet glycoprotein Ia/ IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-354.
• 13 Lewandowski K, Swierczynska A, Kwasnikowski P. et al. The prevalence of C807T mutation of glycoprotein Ia gene among young male survivors of myocardial infarction: a relation with coronary angiography results. Kardiol Pol 2005; 63: 107-113.
• 14 Bojesen SE, Juul K, Schnohr P. et al. City Heart Study: Platelet glycoprotein IIb/ IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol 2003; 42: 661-667.
• 15 Grove EL, Ørntoft TF, Lassen JF. et al. The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction. J Intern Med. 2004; 255: 637-644.
• 16 Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol 2000; 86: 1000-1005.
• 17 Di Castelnuovo A, de Gaetano G, Donati MB. et al. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost 2001; 85: 626-633.
• 18 Carter AM, Mansfield MW, Grant PJ. Polymorphisms of platelet glycoproteins in relation to macrovascular disease in type 2 diabetes mellitus. Diabet Med 1998; 15: 315-319.
• 19 Standards of medical care in diabetes.. American Diabetes Association. Diabetes Care 2004; 27 (Suppl. 01) S5-S1.
• 20 Ishida F, Furihata K, Ishida K. et al. The largest variant of platelet glycoprotein Ib-alpha has four tandem repeats of 13 amino acids in the macroglycopeptide region and a genetic linkage with methionine 145. Blood 1995; 86: 1357-1360.
• 21 Touboul PJ, Hennerici MG, Meairs S. et al. (2007) Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium. Cerebrovasc Dis 2006; 23: 75-80.
• 22 Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. John Wiley & Sons; NY: 1981
• 23 Gonzalez-Conejero R, Lozano ML, Rivera J. et al. Polymorphism of platelet membrane glycoprotein Ib-alfa associated with arterial thrombotic disease. Blood 1998; 92: 2771-2776.
• 24 Ito T, Ishida F, Shimodaira S. et al. Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int J Hematol 1999; 70: 47-51.
• 25 Zotz RB, Winkelmann BR, Müller C. et al. Association of polymorphisms of platelet membrane integrins αIIbβ3 (HPA-1b/Pl^A2) and α2β1 (α2807TT) with premature myocardial infarction. J Thromb Haemost 2005; 3: 1522-1529.
• 26 Tschoepe D, Menart B, Ferber P. et al. Genetic variation of the platelet- surface integrin GP IIb-IIIa (PlA1/A2– SNP) shows a high association with Type 2 diabetes mellitus. Diabetologia 2003; 46: 984-989.
• 27 Rieger S, Endler G, Hsieh K. et al. Reply to: Tschoepe D Menart B Ferber P et al. (2003) genetic variation of the platelet surface integrin GP IIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus. Diabetologia 2004; 47: 761-762.
• 28 Märzi W, Boehm BO, Winkelmann BR. et al. The PlA1/A2 polymorphism of platelet glycoprotein IIIa is not associated with the risk of type 2 diabetes. The Ludwigshafen Risk and Cardiovascular Health Study Diabetologia 2004; 47: 1969-1973.
• 29 Jiménez S, Tàssies D, Espinosa G. et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 835-840.
• 30 Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.